The Melbourne-based biotechnology company confirmed that a recent Type C meeting with the regulator received positive feedback on both the proposed phase 1 trial design and the broader clinical strategy for DEP HER2, a dendrimer-based radioligand therapy for difficult-to-treat cancers.

The trial, known as R327 G301, is progressing across five sites in Indonesia, with patient dosing ongoing and an interim analysis planned once 155 patients have been completed.

Trajan Group Holdings has announced the appointment of long-time executive Simon Billingham as Interim Chief Financial Officer and Interim Joint Company Secretary following the departure of Alister Hodges.

The expansion follows fresh preliminary data from a new cohort of six patients with squamous cell carcinoma, which continued to reinforce a favourable safety profile alongside early signs of efficacy.

AdAlta has taken a step toward addressing one of the most persistent constraints in advanced cancer treatment, signing a memorandum of understanding with Oribiotech and Cell Therapies to deploy next-generation automated manufacturing technology across its pipeline and the broader Asia Pacific region.

Immuron has reported another quarter of steady sales expansion, underpinned by continued demand for its flagship product Travelan, as the company builds momentum across key international markets.

Alterity Therapeutics has moved to deepen its leadership bench at a critical moment in its development, appointing veteran pharmaceutical executive Ann Cunningham to its Board of Directors.

Patrys has announced it has secured commitments to raise approximately $3.2 million through a share placement that drew strong backing from both new and existing investors.

The initiative marks a significant shift for the company, introducing a dual revenue model that combines its established treatment programs with a new stream of sponsor-funded services built on its existing clinical infrastructure.

Atmo Biosciences has moved to strengthen its United States commercial push, appointing seasoned medtech executive Martin Reid as Senior Vice President, Sales, as the company looks to build on early momentum following regulatory clearance and initial market entry.

5 Horizons Ventures and Biointelect have announced a strategic partnership and investment alliance designed to help promising biotech and medtech ventures navigate one of the most challenging phases of development.

The decision opens the door to approximately 51 military hospitals and 170 VA medical centres, dramatically expanding the company’s reach in the United States and positioning it within systems that routinely handle some of the most challenging trauma cases.

Noxopharm has appointed Dr Olivier Laczka as its new Chief Executive Officer with immediate effect, marking a leadership transition as the clinical-stage company positions itself to capitalise on emerging opportunities in its pipeline.

The therapy is being developed to address the underlying cause of Autosomal Dominant Optic Atrophy, a condition that leads to progressive vision loss and currently has no approved treatment options.

The company has named Chisako Mizutani as Country Manager for Japan, bringing more than two decades of experience in clinical research and leadership in contract research organisations.

The trial, spanning multiple centres across the US, is evaluating the performance of RAD 101 in patients with confirmed recurrent brain metastases from a range of solid tumours.

Australian nuclear medicine company Telix Pharmaceuticals has announced a collaboration with Regeneron to develop new targeted cancer treatments.